Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Gross Profit (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Gross Profit for 5 consecutive years, with $29.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gross Profit fell 10.48% year-over-year to $29.2 million, compared with a TTM value of $139.2 million through Dec 2024, down 1.58%, and an annual FY2025 reading of $140.1 million, up 0.64% over the prior year.
  • Gross Profit was $29.2 million for Q4 2024 at Karyopharm Therapeutics, down from $37.5 million in the prior quarter.
  • Across five years, Gross Profit topped out at $125.5 million in Q4 2021 and bottomed at $29.2 million in Q4 2024.
  • Average Gross Profit over 4 years is $42.5 million, with a median of $36.7 million recorded in 2021.
  • The sharpest move saw Gross Profit tumbled 74.74% in 2022, then grew 13.57% in 2024.
  • Year by year, Gross Profit stood at $125.5 million in 2021, then plummeted by 74.74% to $31.7 million in 2022, then grew by 2.9% to $32.6 million in 2023, then dropped by 10.48% to $29.2 million in 2024.
  • Business Quant data shows Gross Profit for KPTI at $29.2 million in Q4 2024, $37.5 million in Q3 2024, and $41.3 million in Q2 2024.